{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:16:24Z","timestamp":1790478984441,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FRN: 142263"],"award-info":[{"award-number":["FRN: 142263"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003877","name":"Idaho Humanities Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.molmet.2019.04.003","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T11:30:34Z","timestamp":1554895834000},"page":"119-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"special_numbering":"C","title":["An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"Joseph","family":"Longo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna E.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Masoomian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixon T.S.","family":"Woon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M.","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodorus H.","family":"van der Kwast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Z.","family":"Penn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.molmet.2019.04.003_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012. CA","volume":"65","author":"Torre","year":"2015","journal-title":"A\u00a0Cancer Journal for Clinicians"},{"issue":"12","key":"10.1016\/j.molmet.2019.04.003_bib2","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.molmet.2019.04.003_bib3","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions","volume":"11","author":"Paller","year":"2013","journal-title":"Clinical Advances in Hematology and Oncology"},{"issue":"4","key":"10.1016\/j.molmet.2019.04.003_bib4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.leu.2402476","article-title":"HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis","volume":"16","author":"Wong","year":"2002","journal-title":"Leukemia"},{"issue":"48","key":"10.1016\/j.molmet.2019.04.003_bib5","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1038\/onc.2012.6","article-title":"Targeting tumor cell metabolism with statins","volume":"31","author":"Clendening","year":"2012","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/j.molmet.2019.04.003_bib6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/jnci\/djj499","article-title":"Statin drugs and risk of advanced prostate cancer","volume":"98","author":"Platz","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"issue":"11","key":"10.1016\/j.molmet.2019.04.003_bib7","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/1055-9965.EPI-07-0448","article-title":"Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort","volume":"16","author":"Jacobs","year":"2007","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"11","key":"10.1016\/j.molmet.2019.04.003_bib8","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1158\/1055-9965.EPI-07-0197","article-title":"Statin use and risk of prostate cancer in the California men's health study cohort","volume":"16","author":"Flick","year":"2007","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"11","key":"10.1016\/j.molmet.2019.04.003_bib9","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1055-9965.EPI-07-0599","article-title":"Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study","volume":"16","author":"Murtola","year":"2007","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"16","key":"10.1016\/j.molmet.2019.04.003_bib10","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2009.27.3003","article-title":"Statin use and risk of prostate cancer recurrence in men treated with radiation therapy","volume":"28","author":"Gutt","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1016\/j.molmet.2019.04.003_bib11","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1002\/cncr.25308","article-title":"Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database","volume":"116","author":"Hamilton","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.molmet.2019.04.003_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2015.0829","article-title":"Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer","volume":"1","author":"Harshman","year":"2015","journal-title":"JAMA Oncology"},{"issue":"6","key":"10.1016\/j.molmet.2019.04.003_bib13","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/annonc\/mdt077","article-title":"Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis","volume":"24","author":"Park","year":"2013","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1016\/j.molmet.2019.04.003_bib14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrc.2016.76","article-title":"The interplay between cell signalling and the mevalonate pathway in cancer","volume":"16","author":"Mullen","year":"2016","journal-title":"Nature Reviews Cancer"},{"issue":"6","key":"10.1016\/j.molmet.2019.04.003_bib15","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1158\/0008-5472.CAN-2148-2","article-title":"Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence","volume":"64","author":"Ettinger","year":"2004","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.molmet.2019.04.003_bib16","doi-asserted-by":"crossref","first-page":"12869","DOI":"10.18632\/oncotarget.7331","article-title":"SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.molmet.2019.04.003_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41588-017-0027-2","article-title":"An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer","volume":"50","author":"Chen","year":"2018","journal-title":"Nature Genetics"},{"issue":"6","key":"10.1016\/j.molmet.2019.04.003_bib18","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/1535-7163.MCT-06-0745","article-title":"Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma","volume":"6","author":"Wong","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.molmet.2019.04.003_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2407-10-103","article-title":"Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance","volume":"10","author":"Martirosyan","year":"2010","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.molmet.2019.04.003_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10549-013-2800-y","article-title":"Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells","volume":"143","author":"Goard","year":"2014","journal-title":"Breast Cancer Research and Treatment"},{"issue":"5","key":"10.1016\/j.molmet.2019.04.003_bib21","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/0008-5472.CAN-17-1231","article-title":"Statin-induced cancer cell death can be mechanistically uncoupled from prenylation of RAS family proteins","volume":"78","author":"Yu","year":"2018","journal-title":"Cancer Research"},{"issue":"37","key":"10.1016\/j.molmet.2019.04.003_bib22","doi-asserted-by":"crossref","first-page":"59640","DOI":"10.18632\/oncotarget.10746","article-title":"High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer","volume":"7","author":"Kimbung","year":"2016","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.molmet.2019.04.003_bib23","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1182\/blood-2009-07-230508","article-title":"Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma","volume":"115","author":"Clendening","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.molmet.2019.04.003_bib24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2018.06.037","article-title":"Atorvastatin versus placebo for prostate cancer before radical prostatectomy \u2013 a randomized, double-blind, placebo-controlled clinical trial","volume":"74","author":"Murtola","year":"2018","journal-title":"European Urology"},{"issue":"4","key":"10.1016\/j.molmet.2019.04.003_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejca.2004.12.013","article-title":"A\u00a0Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix","volume":"41","author":"Knox","year":"2005","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1016\/j.molmet.2019.04.003_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10549-009-0507-x","article-title":"Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer","volume":"119","author":"Garwood","year":"2010","journal-title":"Breast Cancer Research and Treatment"},{"issue":"14","key":"10.1016\/j.molmet.2019.04.003_bib27","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2016.69.7391","article-title":"Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR)","volume":"35","author":"Seckl","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.molmet.2019.04.003_bib28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.eururo.2018.02.019","article-title":"Patient-derived hormone-naive prostate cancer xenograft models reveal growth factor receptor bound protein 10 as an androgen receptor-repressed gene driving the development of castration-resistant prostate cancer","volume":"73","author":"Hao","year":"2018","journal-title":"European Urology"},{"issue":"34","key":"10.1016\/j.molmet.2019.04.003_bib29","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.0910258107","article-title":"Dysregulation of the mevalonate pathway promotes transformation","volume":"107","author":"Clendening","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6257","key":"10.1016\/j.molmet.2019.04.003_bib30","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.molmet.2019.04.003_bib31","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/ijc.25295","article-title":"Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents","volume":"127","author":"Goard","year":"2010","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1016\/j.molmet.2019.04.003_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/VHRM.S1653","article-title":"Clinical efficacy and safety of statins in managing cardiovascular risk","volume":"4","author":"Kapur","year":"2008","journal-title":"Vascular Health and Risk Management"},{"issue":"10","key":"10.1016\/j.molmet.2019.04.003_bib33","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1124\/dmd.107.015677","article-title":"P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a\/b knockout and wild-type mice","volume":"35","author":"Chen","year":"2007","journal-title":"Drug Metabolism and Disposition"},{"issue":"6","key":"10.1016\/j.molmet.2019.04.003_bib34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.cmet.2008.10.008","article-title":"Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance","volume":"8","author":"Radhakrishnan","year":"2008","journal-title":"Cell Metabolism"},{"issue":"12","key":"10.1016\/j.molmet.2019.04.003_bib35","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/S0022-2275(20)30028-6","article-title":"Decreased feedback regulation of low density lipoprotein receptor activity by sterols in leukemic cells from patients with acute myelogenous leukemia","volume":"38","author":"Tatidis","year":"1997","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"10.1016\/j.molmet.2019.04.003_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/1097-0215(20010101)91:1<41::AID-IJC1009>3.0.CO;2-2","article-title":"Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2","volume":"91","author":"Chen","year":"2001","journal-title":"International Journal of Cancer"},{"issue":"4","key":"10.1016\/j.molmet.2019.04.003_bib37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/1535-7163.MCT-13-0797","article-title":"Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling","volume":"13","author":"Li","year":"2014","journal-title":"Molecular Cancer Therapeutics"},{"issue":"17","key":"10.1016\/j.molmet.2019.04.003_bib38","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1158\/0008-5472.CAN-14-0130","article-title":"Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop","volume":"74","author":"Pandyra","year":"2014","journal-title":"Cancer Research"},{"issue":"29","key":"10.1016\/j.molmet.2019.04.003_bib39","doi-asserted-by":"crossref","first-page":"26909","DOI":"10.18632\/oncotarget.4817","article-title":"Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death","volume":"6","author":"Pandyra","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.molmet.2019.04.003_bib40","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"The Journal of Clinical Investigation"},{"issue":"3","key":"10.1016\/j.molmet.2019.04.003_bib41","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1194\/jlr.M064022","article-title":"SREBP-2-deficient and hypomorphic mice reveal roles for SREBP-2 in embryonic development and SREBP-1c expression","volume":"57","author":"Vergnes","year":"2016","journal-title":"Journal of Lipid Research"},{"issue":"2","key":"10.1016\/j.molmet.2019.04.003_bib42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10549-013-2473-6","article-title":"Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial","volume":"138","author":"Bjarnadottir","year":"2013","journal-title":"Breast Cancer Research and Treatment"},{"issue":"23","key":"10.1016\/j.molmet.2019.04.003_bib43","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.295.23.2720-a","article-title":"Statins and the risk of cancer","volume":"295","author":"Duncan","year":"2006","journal-title":"Journal of the American Medical Association"},{"issue":"3","key":"10.1016\/j.molmet.2019.04.003_bib44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1440-1681.2007.04565.x","article-title":"Cholesterol, statins and cancer","volume":"34","author":"Brown","year":"2007","journal-title":"Clinical and Experimental Pharmacology and Physiology"},{"issue":"2","key":"10.1016\/j.molmet.2019.04.003_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrurol.2016.199","article-title":"The current evidence on statin use and prostate cancer prevention: are we there yet?","volume":"14","author":"Alfaqih","year":"2017","journal-title":"Nature Reviews Urology"},{"issue":"15","key":"10.1016\/j.molmet.2019.04.003_bib46","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen Levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.molmet.2019.04.003_bib47","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1172\/JCI200519935","article-title":"Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts","volume":"115","author":"Zhuang","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"issue":"9","key":"10.1016\/j.molmet.2019.04.003_bib48","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.leu.2402196","article-title":"Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells","volume":"15","author":"Xia","year":"2001","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.molmet.2019.04.003_bib49","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/bjc.2014.431","article-title":"In\u00a0vitro and in\u00a0vivo anticancer effects of mevalonate pathway modulation on human cancer cells","volume":"111","author":"Jiang","year":"2014","journal-title":"British Journal of Cancer"},{"issue":"10","key":"10.1016\/j.molmet.2019.04.003_bib50","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/bjc.2012.138","article-title":"The differential effects of statins on the metastatic behaviour of prostate cancer","volume":"106","author":"Brown","year":"2012","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1016\/j.molmet.2019.04.003_bib51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ygyno.2014.08.015","article-title":"Oxysterols synergize with statins by inhibiting SREBP-2 in ovarian cancer cells","volume":"135","author":"Casella","year":"2014","journal-title":"Gynecologic Oncology"},{"issue":"5A","key":"10.1016\/j.molmet.2019.04.003_bib52","doi-asserted-by":"crossref","first-page":"11F","DOI":"10.1016\/j.amjcard.2005.06.008","article-title":"Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions","volume":"96","author":"Mason","year":"2005","journal-title":"The American Journal of Cardiology"},{"issue":"3","key":"10.1016\/j.molmet.2019.04.003_bib53","first-page":"483","article-title":"Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer","volume":"2","author":"Thibault","year":"1996","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1016\/j.molmet.2019.04.003_bib54","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood-2006-08-044446","article-title":"Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin\u00a0+\u00a0high-dose Ara-C: a phase 1 study","volume":"109","author":"Kornblau","year":"2007","journal-title":"Blood"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877819300882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877819300882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:18:14Z","timestamp":1778851094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877819300882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":54,"alternative-id":["S2212877819300882"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2019.04.003","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2019.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 University Health Network. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}